A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor positive (HR+) advanced breast cancer (BC) Meeting Abstract

  

Authors:	Dickler, M. N.; Saura, C.; Richards, D. A.; Krop, I. E.; Cervantes, A.; Bedard, P. L.; Patel, M. R.; Pusztai, L.; Oliveira, M.; Ware, J. A.; Jin, H.; Wilson, T. R.; Stout, T.; Wei, M. C.; Hsu, J. Y.; Baselga, J.
Abstract Title:	A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor positive (HR+) advanced breast cancer (BC)
Meeting Title:	52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	34
Issue:	15 Suppl.
Meeting Dates:	2016 Jun 3-7
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2016-05-20
Start Page:	13s
Language:	English
ACCESSION:	WOS:000404665400027
DOI:	10.1200/JCO.2016.34.15_suppl.520
PROVIDER:	wos
Notes:	Meeting Abstract: 520 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/154918